



## Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

October 25, 2023

FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November:

**Guggenheim Securities 5<sup>th</sup> Annual Inflammation, Neurology & Immunology Conference** in New York, NY

Date: Tuesday, November 7, 2023

Live Webcast: 2:30 p.m. ET

*Management to participate in one-on-one meetings throughout the conference*

**Jefferies London Healthcare Conference** in London, England

Date: Tuesday, November 14, 2023

Live Webcast: 10:30 a.m. ET

*Management to participate in one-on-one meetings throughout the conference*

**Stifel 2023 Healthcare Conference** in New York, NY

Date: Wednesday, November 15, 2023

Live Webcast: 2:25 p.m. ET

*Management to participate in one-on-one meetings throughout the conference*

**Craig-Hallum 14<sup>th</sup> Annual Alpha Select Conference** in New York, NY

Date: Thursday, November 16, 2023

*Management to participate in one-on-one meetings throughout the conference*

**Evercore ISI 6<sup>th</sup> Annual HealthCONx Conference** in Miami, FL

Date: Wednesday, November 29, 2023

Live Webcast: 4:15 p.m. ET

*Management to participate in one-on-one meetings throughout the conference*

To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at <https://investors.phathompharma.com/news-events/events-and-presentations>. Recordings will be available for 90 days following the conclusion of each meeting.

**About Phathom Pharmaceuticals, Inc.**

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company's website at [www.phathompharma.com](http://www.phathompharma.com) and follow the Company on [LinkedIn](#) and [Twitter](#).

**MEDIA CONTACT**

Nick Benedetto

1-877-742-8466

[media@phathompharma.com](mailto:media@phathompharma.com)

**INVESTOR CONTACT**

Eric Sciorilli

1-877-742-8466

[ir@phathompharma.com](mailto:ir@phathompharma.com)

© 2023 Phathom Pharmaceuticals. All rights reserved.